AnalystsAndy ChenAndy Chen's Stock Forecasts
AnalystsAndy Chen
Sectors:
Industries:
Analyst Ranking
Top 9%
#492 out of 5544 analysts
Average Return
+25.91%
Win Rate
50%21 out of 42
Risk vs Reward
Poor
Good
Andy Chen's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Alpine Immune Sciences IncALPN | +546.47% | $10.05 | $64.97 | 2023-10-18 - 2024-05-17 | Strong Buy |
Anaptysbio IncANAB | +193.03% | $16.51 | $48.38 | 2025-02-04 - 2026-02-04 | Buy |
Insmed IncINSM | +175.86% | $28.75 | $79.31 | 2024-02-15 - 2025-02-14 | Buy |
Zenas Biopharma IncZBIO | +157.44% | $7.66 | $19.72 | 2025-02-04 - 2026-02-03 | Buy |
Oruka Therapeutics IncORKA | +143.14% | $14.21 | $34.55 | 2025-02-04 - 2026-02-03 | Buy |
Andy Chen Analyst Color
Get additional color on Andy Chen's coverage of popular stocks
Andy Chen's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Insmed IncINSM | 2 | Hold | N/A | N/A | Downgrades | 8 days ago |
Roivant Sciences LtdROIV | 2 | Hold | N/A | N/A | Downgrades | 8 days ago |
Kymera Therapeutics IncKYMR | 4 | Buy | N/A | N/A | Upgrades | a month ago |
Madrigal Pharmaceuticals IncMDGL | 2 | Buy | $605.00 | +34.52% | Upgrades | 3 months ago |
Spyre Therapeutics IncSYRE | 1 | Hold | N/A | N/A | Downgrades | 3 months ago |
Intellia Therapeutics IncNTLA | 4 | Sell | $9.00 | -21.19% | Downgrades | 3 months ago |
Ionis Pharmaceuticals IncIONS | 2 | Hold | N/A | N/A | Downgrades | 3 months ago |
Sarepta Therapeutics IncSRPT | 2 | Buy | $27.00 | +57.89% | Upgrades | 3 months ago |
Palisade Bio IncPALI | 1 | Buy | $7.00 | +396.45% | Initiates Coverage On | 6 months ago |
Avalo Therapeutics IncAVTX | 1 | Buy | $48.00 | +325.91% | Initiates Coverage On | 6 months ago |
Dianthus Therapeutics IncDNTH | 1 | Buy | $98.00 | +35.94% | Initiates Coverage On | 6 months ago |
Pharvaris NvPHVS | 1 | Buy | $42.00 | +51.41% | Initiates Coverage On | 6 months ago |
Moonlake ImmunotherapeuticsMLTX | 4 | Buy | $24.00 | +151.31% | Upgrades | 7 months ago |
Vera Therapeutics IncVERA | 3 | Buy | $88.00 | +215.64% | Upgrades | 7 months ago |
Apogee Therapeutics IncAPGE | 1 | Hold | N/A | N/A | Initiates Coverage On | 9 months ago |
Immunovant IncIMVT | 3 | Buy | $50.00 | +87.06% | Upgrades | 9 months ago |
Vertex Pharmaceuticals IncVRTX | 2 | Buy | $548.00 | +9.66% | Upgrades | 9 months ago |
Argenx SeARGX | 3 | Hold | N/A | N/A | Downgrades | a year ago |
Apellis Pharmaceuticals IncAPLS | 1 | Hold | N/A | N/A | Initiates Coverage On | a year ago |
Akero Therapeutics IncAKRO | 2 | Hold | N/A | N/A | Downgrades | a year ago |
89bio IncETNB | 2 | Hold | N/A | N/A | Downgrades | a year ago |
Alnylam Pharmaceuticals IncALNY | 3 | Hold | N/A | N/A | Upgrades | a year ago |
Verona Pharma PLCVRNA | 1 | Buy | $170.00 | N/A | Initiates Coverage On | a year ago |
Bridgebio Pharma IncBBIO | 1 | Buy | $49.00 | N/A | Initiates Coverage On | a year ago |
Avidity Biosciences IncRNAM | 1 | Buy | $55.00 | N/A | Initiates Coverage On | a year ago |
Blueprint Medicines CorpBPMC | 1 | Hold | N/A | N/A | Downgrades | a year ago |
Anaptysbio IncANAB | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Crinetics Pharmaceuticals IncCRNX | 1 | Hold | N/A | N/A | Initiates Coverage On | 2 years ago |
Oruka Therapeutics IncORKA | 1 | Buy | $20.00 | N/A | Initiates Coverage On | 2 years ago |
Zenas Biopharma IncZBIO | 1 | Buy | $19.00 | N/A | Initiates Coverage On | 2 years ago |
Incyte CorpINCY | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Celldex Therapeutics IncCLDX | 3 | Hold | N/A | N/A | Downgrades | 2 years ago |
Viridian Therapeutics IncVRDN | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Rapt Therapeutics IncRAPT | 3 | Hold | N/A | N/A | Downgrades | 2 years ago |
Alpine Immune Sciences IncALPN | 3 | Hold | N/A | N/A | Downgrades | 3 years ago |
Crispr Therapeutics AgCRSP | 1 | Hold | N/A | N/A | Initiates Coverage On | 3 years ago |
Affimed NvAFMDQ | 1 | Strong Buy | $60.00 | N/A | Assumes | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.